SEC Comment Letter 0000000000-23-012527 to ELI LILLY & Co (LLY) (CIK 0000059478) (LLY)
ELI LILLY & Co (LLY) (CIK 0000059478)
Date: Nov. 15, 2023 · CIK: 0000059478 · Accession: 0000000000-23-012527
AI Filing Summary & Sentiment
File numbers found in text: 001-06351
Letter
United States securities and exchange commission logo November 15, 2023 Anat Ashkenazi Executive Vice President and Chief Financial Officer Eli Lilly and Company Lilly Corporate Center Indianapolis, IN 46285 Re:Eli Lilly and Company Form 10-K for the fiscal year ended December 31, 2022 Filed February 22, 2023 File No. 001-06351 Dear Anat Ashkenazi: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Donald A. Zakrowski, Senior VP Finance & CAO
Show Raw Text
United States securities and exchange commission logo
November 15, 2023
Anat Ashkenazi
Executive Vice President and Chief Financial Officer
Eli Lilly and Company
Lilly Corporate Center
Indianapolis, IN 46285
Re:Eli Lilly and Company
Form 10-K for the fiscal year ended December 31, 2022
Filed February 22, 2023
File No. 001-06351
Dear Anat Ashkenazi:
We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Donald A. Zakrowski, Senior VP Finance & CAO